Services

  • Core Laboratory

    Imacor AB provides core laboratory services related to image analysis including cardiac magnetic resonance (CMR) images as well as myocardial perfusion SPECT (MPS) images. The Imacor team is certified in GCP (ICH) and operates according to these standards.

    The core laboratory services include assisting in study design, staff training, electronic data transfer, rapid quality assurance on a patient per patient basis, usually within hours of data submission.

    The image analysis methods utilized by Imacor are scientifically validated by the team members 1-7 and specified in standard operating procedures and include assessment of myocardial function, viability, myocardium at risk, myocardial salvage and myocardial salvage index by CMR as well as perfusion and viability assessment by MPS.

  • Study design and statistical analysis

    Imacor AB employees are all PhDs with experience of both experimental and clinical research, mainly related to ischemic heart disease. With a focus on the pathophysiological mechanisms underlying acute and chronic ischemic heart disease in combination with experience with cardiac imaging, Imacor offers assistance in developing appropriate study protocols well suited for the endpoints of interest.  

    Imacor AB can assist in power calculations in preparation for clinical trials based on knowledge of accuracy and precision for the different imaging variables in relation to biochemical markers 13. Imacor AB can also perform statistical analyses of results from a study in preparation for the final study report.

     

     

  • Staff training

    Imacor AB can take the responsibility to develop study specific imaging manual of operations to be distributed among the clinical centres involved in a trial after establishing contact with the persons responsible for imaging at each site. Training by email, phone, webinar and site visits (if necessary) can be handled by Imacor. Training of sites always include submission and quality assessment of qualification patients, preferably two from each site to ensure good quality trial data with minimal data loss as the trial is executed.

     
  • Analysis

    Imacor performs image analysis using an in-house developed, FDA 510(k) approved software called Segment 8. The analysis methods are both in vivo and ex vivo validated 1-7, 9-14 for assessment of left ventricular (LV) end-diastolic and end-systolic volumes, LV mass, LV ejection fraction, regional LV function, aortic and pulmonary blood flow, quantitative myocardial perfusion, myocardium at risk, infarct size, myocardial salvage index.

    The analysis procedures are standardized and described in standard operating procedures. The quantitative assessment and the subsequent analysis of the imaging data is performed by either Professor Håkan Arheden, Associate Professor Marcus Carlsson or Associate Professor Henrik Engblom, all senior researchers in the Lund cardiac MR group, Lund University, Lund, Sweden.

  • Web-based image data transfer and rapid quality feedback

    Imacor offers a unique image data transfer solution called Segment Transfer. Segment transfer is a secure web-based imaging transfer protocol which is easy to use at site and enables quick feedback, usually within hours, to the site and to the study steering committee for each patient. Furthermore, it enables the study monitors to follow the status of patient inclusion online in real time. Consecutive image data will be transferred to Imacor for quality control.

    Imacor distributes the Segment Transfer software and is responsible for the education of each site and the study monitors of how to operate the software.

     

Referenses

  1. Carlsson M, Ubachs JF, Hedstrom E, Heiberg E, Jovinge S, Arheden H. Myocardium at risk after acute infarction in humans on cardiac magnetic resonance: quantitative assessment during follow-up and validation with single-photon emission computed tomography. JACC Cardiovasc Imaging 2009;2:569-76. DOI: 10.1016/j.jcmg.2008.11.018
  2. Engblom H, Tufvesson J, Jablonowski R, et al. A new automatic algorithm for quantification of myocardial infarction imaged by late gadolinium enhancement cardiovascular magnetic resonance: experimental validation and comparison to expert delineations in multi-center, multi-vendor patient data. J Cardiovasc Magn Reson 2016;18:27. DOI: 10.1186/s12968-016-0242-5
  3. Heiberg E, Engblom H, Engvall J, Hedstrom E, Ugander M, Arheden H. Semi-automatic quantification of myocardial infarction from delayed contrast enhanced magnetic resonance imaging. Scand Cardiovasc J 2005;39:267-75. DOI: 10.1080/14017430500340543
  4. Heiberg E, Ugander M, Engblom H, et al. Automated quantification of myocardial infarction from MR images by accounting for partial volume effects: animal, phantom, and human study. Radiology 2008;246:581-8. DOI: 10.1148/radiol.2461062164
  5. Nordlund D, Klug G, Heiberg E, et al. Multi-vendor, multicentre comparison of contrast-enhanced SSFP and T2-STIR CMR for determining myocardium at risk in ST-elevation myocardial infarction. Eur Heart J Cardiovasc Imaging 2016. DOI: 10.1093/ehjci/jew027
  6. Sorensson P, Heiberg E, Saleh N, et al. Assessment of myocardium at risk with contrast enhanced steady-state free precession cine cardiovascular magnetic resonance compared to single-photon emission computed tomography. J Cardiovasc Magn Reson 2010;12:25. DOI: 10.1186/1532-429X-12-25
  7. Ubachs JF, Sorensson P, Engblom H, et al. Myocardium at risk by magnetic resonance imaging: head-to-head comparison of T2-weighted imaging and contrast-enhanced steady-state free precession. Eur Heart J Cardiovasc Imaging 2012;13:1008-15. DOI: 10.1186/1471-2342-10-1
  8. Heiberg E, Sjogren J, Ugander M, Carlsson M, Engblom H, Arheden H. Design and validation of Segment--freely available software for cardiovascular image analysis. BMC Med Imaging 2010;10:1. DOI: 10.1186/1471-2342-10-1
  9. Jablonowski R, Engblom H, Kanski M, et al. Contrast-Enhanced CMR Overestimates Early Myocardial Infarct Size: Mechanistic Insights Using ECV Measurements on Day 1 and Day 7. JACC Cardiovasc Imaging 2015;8:1379-89. DOI: 10.1016/j.jcmg.2015.08.015
  10. Ubachs JF, Engblom H, Koul S, et al. Myocardium at risk can be determined by ex vivo T2-weighted magnetic resonance imaging even in the presence of gadolinium: comparison to myocardial perfusion single photon emission computed tomography. Eur Heart J Cardiovasc Imaging 2013;14:261-8. DOI: 10.1093/ehjci/jes142
  11. Bloch KM, Carlsson M, Arheden H, Stahlberg F. Quantifying coronary sinus flow and global LV perfusion at 3T. BMC Med Imaging 2009;9:9. DOI: 10.1186/1471-2342-9-9
  12. Carlsson M, Andersson R, Bloch KM, et al. Cardiac output and cardiac index measured with cardiovascular magnetic resonance in healthy subjects, elite athletes and patients with congestive heart failure. J Cardiovasc Magn Reson 2012;14:51. DOI: 10.1186/1532-429X-14-51
  13. Engblom H, Heiberg E, Erlinge D, et al. Sample Size in Clinical Cardioprotection Trials Using Myocardial Salvage Index, Infarct Size, or Biochemical Markers as Endpoint. J Am Heart Assoc 2016 March 9;4(3). DOI: 10.1161/JAHA.115.002708
  14. Engblom H, Xue H, Akil S et al. Fully quantitative cardiovascular magnetic resonance myocardial perfusion ready for clinical use: a comparison between cardiovascular magnetic resonance imaging and positron emission tomography. J Cardiovasc Magn Reson 2017;19:78. DOI: 10.1186/s12968-017-0388-9
Imacor AB   |   Lund, Sweden   |   This email address is being protected from spambots. You need JavaScript enabled to view it.  |   Cookies/GDPR
design & produktion: SL Development - responsiva webbplatser som fungerar på allt från datorer till smarta mobiltelefoner
Copyright © Imacor AB. All Rights Reserved.